Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/16/2024 | $5.00 → $3.00 | Outperform → Market Perform | Leerink Partners |
| 2/1/2022 | $10.00 | Outperform | RBC Capital Mkts |
Gainers Viracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday's pre-market session. The company's market cap stands at $26.7 million. Purple Biotech (NASDAQ:PPBT) stock increased by 14.48% to $0.63. The market value of their outstanding shares is at $16.4 million. Akanda (NASDAQ:AKAN) stock rose 12.54% to $3.05. The market value of their outstanding shares is at $5.8 million. Viridian Therapeutics (NASDAQ:VRDN) shares rose 12.09% to $13.7. The market value of their outstanding shares is at $874.2 million. IGC Pharma (AMEX:IGC) shares increased by 11.21% to $0.48. The company's market cap stands at $36.1 million. OpGen (NASDAQ:OPGN) shares moved upwards by
Oppenheimer analyst Hartaj Singh maintains Viracta Therapeutics (NASDAQ:VIRX) with a Outperform and lowers the price target from $13 to $11.
SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)
SC 13G - Viracta Therapeutics, Inc. (0001061027) (Subject)
SC 13D/A - Viracta Therapeutics, Inc. (0001061027) (Subject)
- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val's substantial antitumor activity and generally well-tolerated safety profile - - Productive FDA meeting held to align on a potential regulatory path forward for Nana-val in patients with relapsed or refractory EBV-positive PTCL - - Updated Nana-val clinical development plan implemented to optimize its clinical benefit in EBV-positive PTCL patients and expedite a randomized controlled trial to support potential registration - - Viracta to host conference call and webcast on Wednesday, August 14 at 8:
– LENZ Therapeutics to debut on Nasdaq under the ticker symbol "LENZ" as a publicly traded company advancing late clinical-stage assets for the treatment of presbyopia – – Topline data from registration-enabling Phase 3 CLARITY trials for lead assets LNZ100 and LNZ101 expected in April 2024 – – Strong balance sheet with approximately $210 million of cash and cash equivalents, including $53.5 million from a concurrent PIPE financing – LENZ Therapeutics, Inc. (NASDAQ:LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced th
- Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data from expansion phase of the Phase 2 NAVAL-1 clinical trial of Nana-val in the first half of 2025 - - Determined recommended Phase 2 dose of Nana-val in patients with advanced EBV-positive solid tumors - SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported financial
SAN DIEGO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that the company has implemented a reprioritization of resources intended to enhance the company's focus on its Nana-val development program in patients with relapsed or refractory (R/R) EBV-positive peripheral T-cell lymphoma (PTCL). To further align resources with current pipeline priorities, Viracta is announcing today that it has implemented a further reduction in force that impacts approximately 42% of the company's employees. Viracta ex
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place in New York City on Wednesday, September 11, 2024, at 8:30 a.m. EDT. A live webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Presentations" and archived for 90 days. About Viracta Therapeutics, Inc.Viracta is a clinical-stage precision o
Leerink Partners downgraded Viracta Therapeutics from Outperform to Market Perform and set a new price target of $3.00 from $5.00 previously
RBC Capital Mkts initiated coverage of Viracta Therapeutics with a rating of Outperform and set a new price target of $10.00
HC Wainwright & Co. initiated coverage of Viracta Therapeutics with a rating of Buy and set a new price target of $35.00
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
10-Q - Viracta Therapeutics, Inc. (0001061027) (Filer)
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
4 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Michael Faerm as Viracta's new Chief Financial Officer, Viracta's Board of Directors granted Mr. Faerm a non-qualified stock option to purchase 500,000 shares of common stock under Viracta's 2021 Inducement Equity Incentive Plan. Additionally, Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase 10,000 shares of common stock. Each optio
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financial Officer, effective immediately. Mr. Faerm is a seasoned biotech executive with more than 25 years of experience in life sciences companies, equity research and investment banking. "We are delighted to welcome Mike, an accomplished life sciences industry & Wall Street veteran, who we believe will be instrumental in supporting our next phase of development," said Mark Rothera, President and Chief E
SAN DIEGO, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Darrel P. Cohen, M.D., Ph.D. as Viracta's new Chief Medical Officer, the Compensation Committee of Viracta's Board of Directors granted Dr. Cohen a non-qualified stock option to purchase 235,000 shares of common stock under Viracta's 2021 Inducement Equity Incentive Plan. The option vests over four years, with 25% vesting on the one-year anniversary of Dr. Cohen's employment commencement date and the rem